Abstract
The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.
| Original language | English |
|---|---|
| Article number | 633 |
| Number of pages | 8 |
| Journal | Frontiers in Pharmacology |
| Volume | 8 |
| DOIs | |
| Publication status | Published - 22 Sep 2017 |
Keywords
- Cell therapy
- Fibrosis
- Mesenchymal stem cells
- Progenitor cells
- Stem cells and regenerative medicine
Cite this
}
Cell-based therapies for tissue fibrosis. / Lim, Rebecca; Ricardo, Sharon D.; Sievert, William.
In: Frontiers in Pharmacology, Vol. 8, 633, 22.09.2017.Research output: Contribution to journal › Review Article › Research › peer-review
TY - JOUR
T1 - Cell-based therapies for tissue fibrosis
AU - Lim, Rebecca
AU - Ricardo, Sharon D.
AU - Sievert, William
PY - 2017/9/22
Y1 - 2017/9/22
N2 - The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.
AB - The development of tissue fibrosis in the context of a wound-healing response to injury is common to many chronic diseases. Unregulated or persistent fibrogenesis may lead to structural and functional changes in organs that increase the risk of significant morbidity and mortality. We will explore the natural history, epidemiology, and pathogenesis of fibrotic disease affecting the lungs, kidneys, and liver as dysfunction of these organs is responsible for a substantial proportion of global mortality. For many patients with end-stage disease, organ transplantation is the only effective therapy to prolong life. However, not all patients are candidates for the major surgical interventions and life-long immunosuppression required for a successful outcome and donor organs may not be available to meet the clinical need. We will provide an overview of the latest treatment strategies for these conditions and will focus on stem or progenitor cell-based therapies for which there is substantial pre-clinical evidence based on animal models as well as early phase clinical trials of cell-based therapy in man.
KW - Cell therapy
KW - Fibrosis
KW - Mesenchymal stem cells
KW - Progenitor cells
KW - Stem cells and regenerative medicine
UR - http://www.scopus.com/inward/record.url?scp=85030101187&partnerID=8YFLogxK
U2 - 10.3389/fphar.2017.00633
DO - 10.3389/fphar.2017.00633
M3 - Review Article
VL - 8
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
M1 - 633
ER -